RE:RE:RE:RE:RE:RE:Bayer looking for a "mid-size M&A transaction" in oncologyPharma giant Bayer is launching a precision health unit. "We believe we can help consumers move from reactive to proactive aging, with individualized insights about their biological age at all stages of life," said Heiko Schipper, president of Bayer's consumer health division.
Schipper pointed to Bayer's work with Edifice Health, a company that uses state-of-the-art ‘omics’ platforms and advanced artificial intelligence to generate a biomarker composite score for systemic chronic inflammation, a core driver of many age-related diseases including cancer, cardiovascular disease and autoimmune disease.